InterCure Ltd.
NASDAQ:INCRDrug Manufacturers - Specialty & Generic
-$0.04 today
- Market cap
- $51.63M
- Beta
- 0.57
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$0.64
Volume 0.01M
Average 0.04M
INCR Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
InterCure Ltd.NASDAQ: INCR
Gross Margin · Q2 FY2025 · quarter ended Jun 2025
Gross margin narrows to 30.9%
Gross margin was 30.9% in Q2 FY2025, down 2.2 pp from a year earlier. On a trailing-twelve-month basis it was 16.7%, down 11.9 pp year over year. Over 3 fiscal years it narrowed by 27.6 pp.
Context
- Gross margin widened in 0 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 12.3%
- Year-over-year change
- -0.4pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.3% | -0.4pp |
| FY2024 | 2024-12-31 | 12.7% | -16.9pp |
| FY2023 | 2023-12-31 | 29.6% | -10.3pp |
| FY2022 | 2022-12-31 | 39.9% | -1.6pp |
| FY2021 | 2021-12-31 | 41.5% | — |
Gross Margin vs competitors
How INCR compares with its peers on the latest reported figures
- INCR's LTM Jun 2025 gross margin of 16.7% is the lowest of the 6 companies compared; the peer median is 60.3%.
- Its year-over-year change of -11.9 pp is the 5th highest of 6, against a peer median of +5.4 pp.
- Over three fiscal years its change of -27.6 pp compares with a peer median of +3.0 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 76.2% | +30.8 pp | — | |
| LTM Mar 2026 | 64.5% | +3.3 pp | +7.6 pp | |
HYFTMindWalk Holdings Corp. | LTM Jan 2026 | 60.3% | +10.9 pp | -1.5 pp |
| LTM Mar 2026 | 49.7% | +5.4 pp | +11.2 pp | |
| LTM Mar 2026 | 44.3% | -17.8 pp | -43.1 pp | |
| LTM Jun 2025 | 16.7% | -11.9 pp | -27.6 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding INCR) | 60.3% | +5.4 pp | +3.0 pp | |
Competitors are the stored peer set for INCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 219.68M | 388.68M | 355.55M | 238.85M | 270.2M |
| Cost of Revenue | 128.55M | 233.6M | 250.46M | 208.61M | 237.02M |
| Gross Profit | 91.13M | 155.08M | 105.1M | 30.23M | 33.18M |
| Gross Margin | 41.5% | 39.9% | 29.6% | 12.7% | 12.3% |
| Research & Development | 1.24M | 632K | 388K | 414K | 390K |
| Selling, General & Admin | 53.46M | 97.32M | 86.24M | 84.63M | 80.41M |
| Operating Expenses | 62.95M | 104.46M | 146.66M | 97.44M | 26.45M |
| Depreciation & Amortization | 7.39M | 11.7M | 13.17M | 15.37M | 17.15M |
| EBITDA | 31.17M | 70.23M | (23.9M) | (51.31M) | (7.29M) |
| EBITDA Margin | 14.2% | 18.1% | -6.7% | -21.5% | -2.7% |
| Operating Income | 28.19M | 50.63M | (41.57M) | (67.21M) | 6.73M |
| Operating Margin | 12.8% | 13.0% | -11.7% | -28.1% | 2.5% |
| Interest Income | 130K | 844K | 4.55M | 2.7M | 1.56M |
| Interest Expense | 5.05M | 14.69M | 24.22M | 20.65M | 19.66M |
| Other Income / Expenses | (9.45M) | (6.79M) | (19.72M) | (20.12M) | (50.84M) |
| Income Before Tax | 18.74M | 43.84M | (61.29M) | (87.32M) | (44.1M) |
| Pre-Tax Margin | 8.5% | 11.3% | -17.2% | -36.6% | -16.3% |
| Income Tax Expense | 11.44M | 93K | 2.25M | (14.53M) | (7.32M) |
| Net Income | 4.69M | 44.82M | (61.96M) | (67.8M) | (35.71M) |
| Net Margin | 2.1% | 11.5% | -17.4% | -28.4% | -13.2% |
| EPS (Basic) | 0.12 | 0.99 | (1.36) | (1.42) | (0.63) |
| EPS (Diluted) | 0.11 | 0.99 | (1.36) | (1.42) | (0.63) |
| Weighted Avg Shares | 38.49M | 45.35M | 45.56M | 47.77M | 56.8M |
| Weighted Avg Shares (Diluted) | 40.84M | 45.35M | 45.57M | 47.77M | 56.8M |
InterCure Ltd.
NASDAQ:INCR
Intrinsic Alpha fair value
Locked
Current Price
$3.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.